25-27kDa& 47-55kDa (Reducing)
PBS PH7.4 5% trehalose
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
1. Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53.
2. Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. The Journal of Pain, 2009, 10(4): S44.
Tanezumab (RN-624) is a humanized anti-NGF monoclonal antibody with high affinity and specificity. It blocks NGF from binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab is applicable in studies of acute and chronic pain, including osteoarthritis, knee pain, neuralgia, and post-herpetic neuralgia.
1μg (R: reducing condition).
The purity of Anti-β-NGF Monoclonal Antibody (Tanezumab) is greater than 95% as determined by SEC-HPLC.
Immobilized Recombinant Human Beta-NGF (Mammalian) at 2μg/mL (100μL/well) can bind Anti-β-NGF Monoclonal Antibody (Tanezumab) (Cat. No. UA011217) with EC50 of 5.05-7.07ng/mL.
您现在的位置：